Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.
about
Challenges and opportunities in estimating viral genetic diversity from next-generation sequencing dataDefining the fitness of HIV-1 isolates with dual/mixed co-receptor usageMolecular epidemiology of HIV in two highly endemic areas of northeastern South Africa.Genotypic tropism testing by massively parallel sequencing: qualitative and quantitative analysis.The utility of genotypic tropism testing in clinical practice.HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to MaravirocCorrelation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods.Copy Number Variation within Human β-Defensin Gene Cluster Influences Progression to AIDS in the Multicenter AIDS Cohort Study.Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments.Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load.Discordance in HIV-1 co-receptor use prediction by different genotypic algorithms and phenotype assay: intermediate profile in relation to concordant predictions.
P2860
Q28727944-27C2E968-B616-4238-B4C5-9307ECF9C0F7Q30278577-BA349E77-F4D2-47A5-9E63-674D04BCC2DDQ30357556-4159B82D-97EA-4080-B8E8-E89AA95EABABQ33899080-941AB9CC-61DD-463E-BDB0-88377BFD77E2Q35229633-8AF63174-261C-409A-B192-487B416BC152Q35662019-69E546AA-126D-44E5-8F3A-24C48B31683AQ35806266-4E178883-99BB-4980-B0BC-E6224CCC3A38Q36723354-69DE906A-01C8-4FBB-A204-0714E50C4FD2Q37460123-C3A9E4AA-B8E9-4132-9AB6-FC93BD7D8CF0Q39563189-9BDC2AEE-AD4F-40FD-8F2F-4517680FAA9DQ51450830-E20D452E-7535-44C1-A19D-41E722C9CE69
P2860
Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Comparison of phenotypic and g ...... gible for maraviroc treatment.
@ast
Comparison of phenotypic and g ...... gible for maraviroc treatment.
@en
Comparison of phenotypic and g ...... gible for maraviroc treatment.
@nl
type
label
Comparison of phenotypic and g ...... gible for maraviroc treatment.
@ast
Comparison of phenotypic and g ...... gible for maraviroc treatment.
@en
Comparison of phenotypic and g ...... gible for maraviroc treatment.
@nl
prefLabel
Comparison of phenotypic and g ...... gible for maraviroc treatment.
@ast
Comparison of phenotypic and g ...... gible for maraviroc treatment.
@en
Comparison of phenotypic and g ...... gible for maraviroc treatment.
@nl
P2093
P2860
P50
P356
P1476
Comparison of phenotypic and g ...... gible for maraviroc treatment.
@en
P2093
Anna Maria Geretti
Chris Verhofstede
Dirk Vogelaers
Dolores Vaira
Els Demecheleer
Herwig Van Marck
Ina Vandenbroucke
Kabamba Kabeya
Katrien Fransen
P2860
P304
P356
10.1093/JAC/DKQ458
P407
P577
2010-12-31T00:00:00Z